Bend Research Highlights Biotherapeutics Capabilities

May 7, 2013

Bend, Ore. – May 7, 2013 – Bend Research Inc., a leading independent scientific development and manufacturing company, announced it will participate in several May events focused on achieving value and advancing health through innovations in biotherapeutics.

“Since Bend Research launched our biotherapeutics development initiative last year, we’ve been able to offer new technologies and equipment proven to improve biotherapeutic and vaccine production,” said Dr. Lisa Graham, senior vice president of Bend Research.  “We are eager to meet with clients and industry peers at conferences this month to share insights we’ve gained about biotherapeutic products and processes.”

Bend Research scientists will participate in the following meetings.

  • 2nd Annual Biopharmaceutical Process and Quality Consortium Summit, May 13-15, Lowell, Mass.: Bend Research will attend and sponsor this event focused on next-generation technologies for biopharmaceutical processes.
  • IBC’s 9th Annual Cell Line Development & Engineering Conference, May 20-22, La Jolla, Calif.: Dr. Graham will chair the session titled, “Developing Cell Lines for Biosimilars,” at 1:00 p.m. May 22 and present a talk titled, “Data Integration Methodology that Leverages Coupled Bioreactor Analytics, Automated Sampling, and Applied Mathematics to Redefine Bioreactor Operation: Case Study Example Illustrating Impact on Cell Culture Productivity,” at 3:30 p.m. May 22.
  • 2013 AAPS National Biotechnology Conference, May 20-22, San Diego, Calif.: Mike Burke, a senior research scientist at Bend Research, will present a poster titled, “Stabilization of Biotherapeutic Formulations using a Spray-Dry Manufacture Process,” from 5:30-6:30 p.m. May 21.

Contact:   To schedule an interview or meeting with Bend Research experts or for any other press inquiry, please contact Phoenix Barringer at or 541-382-4100.

About Bend Research Inc.

For more than 35 years, Bend Research Inc. has worked with clients to create value by advancing new medicines that improve human health and to solve their most difficult scientific and technical problems.  This success is based on the company’s ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding.

Bend Research Inc. provides several capabilities, including formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facilities, and advances promising drug candidates from conception through commercialization. The company is a leader in novel formulations, including spray-dried dispersions and hot-melt extrusion formulations, as well as controlled-release, inhalation, and biotherapeutics technologies. With more than 285 employees, Bend Research Inc. is based in six state-of-the-art facilities in Bend, Oregon, USA.

Follow Bend Research on LinkedIn at  For more information, visit